Reference

Last reviewed: 29 Apr 2026
Sources cited: 8
Residues: 29

Primary structure29 residues · 3,357.93 Da

01TyrTyrosine

02AlaAlanine

03AspAspartate

04AlaAlanine

05IleIsoleucine

06PhePhenylalanine

07ThrThreonine

08AsnAsparagine

09SerSerine

10TyrTyrosine

11ArgArginine

12LysLysine

13ValValine

14LeuLeucine

15GlyGlycine

16GlnGlutamine

17LeuLeucine

18SerSerine

19AlaAlanine

20ArgArginine

21LysLysine

22LeuLeucine

23LeuLeucine

24GlnGlutamine

25AspAspartate

26IleIsoleucine

27MetMethionine

28SerSerine

29ArgArginine

Nonpolar Polar Acidic Basic Aromatic Gly/Pro

Sermorelin

Last verified: 2026-04-29

At a glance


Also known as	GRF(1-29), Geref, Geref Diagnostic, sermorelin acetate
Class	Synthetic GHRH analogue — native human GHRH(1-29), the shortest fully active fragment
Typical route	Subcutaneous injection, 1–2× daily
Half-life	~11–12 minutes (subQ or IV)1
Molecular weight	3,357.93 Da
Sequence	Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg (29 amino acids — native human GHRH(1-29) with free C-terminal amide; no stability substitutions)
UK status	Not approved. No licensed product. Sold as a research chemical.
US status	Previously FDA-approved as Geref (1997–2009). Withdrawn from market 2008/2009 for commercial/manufacturing reasons explicitly not for safety or effectiveness, per the May 2009 Federal Register notice.2 Currently accessible through 503A compounding pharmacies under physician prescription.

What it is

Sermorelin is the native human GHRH(1-29) sequence — the shortest fragment of growth hormone-releasing hormone that retains full biological activity. It is the parent compound that CJC-1295 was engineered from: CJC-1295 is sermorelin with four stability-conferring amino-acid substitutions plus, in the DAC variant, an albumin-binding modification.

The pharmacology and indication are identical to CJC-1295 no-DAC: ask the pituitary GHRH receptor to release a pulse of growth hormone. The differences are:

Half-life. Sermorelin clears in 11–12 minutes; CJC-1295 no-DAC in roughly 30 minutes. Both produce a brief GHRH-receptor pulse, but sermorelin’s is sharper.
FDA history. Sermorelin was approved by the FDA as Geref in 1997 for paediatric growth hormone deficiency. EMD Serono withdrew it in 2008–2009 for commercial reasons; the FDA’s Federal Register notice confirms the withdrawal was not for safety or efficacy concerns. This is a meaningful credibility marker for users who care about regulatory provenance.
Compounding-pharmacy access (US). Because sermorelin has a documented FDA history and an established prescribing record, it is one of the GH-pathway peptides most accessibly available through 503A compounding pharmacies in the United States. This is a different access path from CJC-1295 or ipamorelin (which are in active regulatory flux as of April 2026 and do not have the same compounding-pharmacy footprint).

It is not human growth hormone. Like CJC-1295 and ipamorelin, sermorelin asks your pituitary to release more of its own GH; it doesn’t replace GH.

Mechanism

Sermorelin is a full agonist at the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs. GHRH-R activation drives Gs-coupled cAMP elevation, depolarises somatotrophs, and triggers GH exocytosis — the same intracellular pathway as native GHRH and as CJC-1295.5

The mechanism distinguishes sermorelin from CJC-1295 and ipamorelin in three ways:

It is the native fragment, unmodified. CJC-1295 carries four stability substitutions; sermorelin doesn’t. Sermorelin’s clearance by DPP-IV and other peptidases is what gives it the ~11-minute half-life — the trade-off for being “natural” rather than engineered.
Negative feedback through somatostatin is preserved. Because sermorelin is an exact GHRH(1-29) fragment, the body’s normal GHRH/somatostatin counter-regulation responds to it the way it responds to endogenous GHRH. This is the basis for the claim that sermorelin produces the most physiologically natural GH release pattern in the GHRH class — receptor activation comes and goes; the somatostatin brake remains intact; the resulting GH pulse follows the body’s normal rhythms.
Pulse magnitude is smaller than CJC-1295 no-DAC’s. The shorter half-life means less GHRH-receptor occupancy time per dose. In direct mechanistic terms, the GH pulse from a single sermorelin dose is somewhat smaller than from an equimolar no-DAC dose; CJC-1295’s stability modifications were specifically designed to extend the receptor pulse.

The synergy with ipamorelin (or other GHRPs) operates the same way as CJC-1295 no-DAC + ipamorelin: GHRH-R + GHSR-1a co-stimulation acts through non-overlapping intracellular pathways, producing 3–5× higher GH release than either alone. Sermorelin + ipamorelin is a less common stack than CJC-1295 + ipamorelin in the biohacker space but is the clinically equivalent pairing through a US compounding-pharmacy route.

Routes of administration

Subcutaneous injection (the standard route)


Bioavailability	Sufficient to drive a measurable GHRH pulse
Onset	GH pulse peaks ~15–30 minutes post-injection
Duration	1–2 hours per dose; full clearance well under 6 hours
Typical dose (this route)	100–500 mcg per injection, 1–2× daily
Equipment	Insulin syringe (29G–31G, U-100), bacteriostatic water, alcohol wipes
When this route makes sense	Default and standard. The original Geref approval was for subQ; clinical literature is dominated by subQ data.

Bedtime dosing is standard for the same reasons as CJC-1295 and ipamorelin: aligned with night-time GH pulse, easier to maintain the fasted state required for full pulse response, recovery effects overlap with sleep.

Intravenous (historical / diagnostic)


Bioavailability	100% by definition
Use case	Geref Diagnostic was approved for IV administration as a paediatric GH-stimulation test
Typical dose	1 mcg/kg IV bolus for the diagnostic test
When this route makes sense	Clinical diagnostic only. Not relevant to community use.

The IV route is documented in the Geref FDA labelling because the diagnostic formulation was used for paediatric growth-hormone-deficiency workup. It has no place in community protocols.

Intramuscular injection


Bioavailability	Comparable to subQ; absorption faster
Typical dose	Same as subQ
When this route makes sense	Rarely chosen. SubQ is mechanically easier and equivalent for GH pulse outcomes.

Oral / sublingual / intranasal

Not viable. Sermorelin is GI-degraded; sublingual and intranasal absorption are insufficient to produce reliable GH pulses for a 29-residue peptide.

Cross-route comparison

SubQ at bedtime is the standard. IM is mechanically equivalent but practically unused. IV is diagnostic only. The route question for sermorelin is timing (fasted, evening) and stack pairing, not which administration route.

What the evidence says

Honest summary: sermorelin is the GHRH compound with the most regulatory provenance — FDA-approved for paediatric GHD from 1997 to 2009, with documented short-term efficacy in that population. Adult and biohacker use is extrapolation from the paediatric record and from short-term endocrinology studies; long-term outcome data in healthy adults is essentially absent.

Pediatric growth hormone deficiency (the FDA-approval indication)

The clinical record sermorelin was approved on is paediatric GHD. A 1996 study showed 74% of children with idiopathic GHD had a clear growth response to daily sermorelin injections within 6 months. Six-month treatment increased GH release and growth velocity in this population.1 7

The most common adverse event in the paediatric trials was transient injection-site pain, redness, or swelling in approximately 16% of patients. No serious safety signals were identified that drove the eventual withdrawal.

This evidence base supports sermorelin’s use in growing children with documented GHD. It does not, by itself, support adult anti-ageing use, recovery use, or body-composition use. The compound’s mechanism is the same; the outcome data isn’t.

The 2008/2009 withdrawal — why it matters

EMD Serono notified the FDA in December 2008 of GEREF discontinuation. The FDA published the Federal Register notice on May 19, 2009, withdrawing approval effective June 18, 2009. The Federal Register notice explicitly states the withdrawal was not for reasons of safety or effectiveness.2 Industry sources cite manufacturing difficulties with the active ingredient and a small commercial market as the actual reason.

This matters editorially. Regulatory withdrawals are common, but withdrawals for safety reasons end a compound’s credibility. Sermorelin’s withdrawal was the opposite — the regulatory record explicitly preserves the safety position. This is the strongest regulatory provenance of any compound in the GH-axis cluster of this encyclopedia.

Adult-onset GHD evidence

A 2009 review (Walker, Clin Interventions in Aging) argued sermorelin is a “better approach” than rhGH for adult-onset GHD on the grounds that it preserves the somatostatin feedback loop and produces a more physiological GH release pattern.6 The evidence base in adult GHD is genuinely smaller than the paediatric base — most published trials are short, smaller-N, and not in the sponsor-led registrational format that built the paediatric record.

What the evidence does NOT show

No long-term outcome data in healthy adults. “Anti-ageing” or “longevity” claims are not directly supported by sermorelin trials.
No body-composition outcome trials. Most claims rest on the chain GH-pulse → IGF-1 → favourable body composition, with each step inferred rather than measured.
No head-to-head with HGH at clinically meaningful durations.
No characterisation of receptor desensitisation with chronic use beyond what’s documented for the paediatric protocol.
No comparative trials of sermorelin vs CJC-1295 — the choice between them is reasoned, not measured.

The compound’s pharmacology is real and the paediatric efficacy is documented. The downstream claims biohackers care about — body composition, recovery, sleep depth, longevity — are extrapolation, not direct evidence.

Typical use patterns

Sermorelin monotherapy (the compounding-pharmacy mainstream)

For users accessing sermorelin through US compounding pharmacies under physician supervision, monotherapy is the most common pattern:

200–500 mcg subQ at bedtime, 5 nights per week
Some prescribers use lower doses (100–200 mcg) for cautious starts and adult patients, particularly older patients
Cycles of 3–6 months on, 1–2 months off, mirroring the receptor-desensitisation precaution from the broader GH-secretagogue literature

This pattern is the closest thing in the GH cluster to a “clinical” protocol — there’s a prescriber, a pharmacy, a documented compound, and a billing trail. Users care about that for credibility, legal posture, or insurance reasons.

Sermorelin + ipamorelin (the GH-stack equivalent of CJC-1295 + ipamorelin)

Compounding pharmacies will commonly dispense a combined sermorelin + ipamorelin formulation, mirroring the no-DAC + ipamorelin community stack but through the prescription pathway:

200–300 mcg sermorelin + 200–300 mcg ipamorelin, subQ at bedtime
Same fasted-dosing requirement as CJC-1295 stacks
Same 5-on/2-off weekly pattern, same cycle convention

The pharmacological case is the same as CJC-1295 + ipamorelin: GHRH-R + GHSR-1a co-stimulation through non-overlapping pathways. The practical difference is access route — sermorelin has a real prescription pathway in the US that CJC-1295 does not, as of April 2026.

Why a user would choose sermorelin over CJC-1295

Regulatory provenance. FDA-approval history, current 503A compounding-pharmacy access, prescriber pathway in the US.
Physiological pulse pattern. Native GHRH(1-29) preserves somatostatin feedback in a way the CJC-1295 stability substitutions theoretically don’t (mechanistically argued; not directly compared).
Insurance / legitimacy. A prescription for compounded sermorelin is different from a research-chem purchase, even if the underlying pharmacology overlaps.

Why a user would choose CJC-1295 over sermorelin

Pulse amplitude and duration. No-DAC’s 30-minute window is roughly 2–3× sermorelin’s, producing a measurably larger GH pulse per dose.
Cost (research-chem path). Research-chem CJC-1295 is generally cheaper than compounded sermorelin in markets where both are accessible.
Convenience (DAC variant). Once-weekly DAC dosing has no sermorelin equivalent; sermorelin will never produce sustained elevation regardless of dose.

Stacking beyond ipamorelin

BPC-157 / TB-500: common pairing during recovery phases. No documented interactions.
NAD+ precursors, MOTS-c: common in longevity stacks. No documented interactions.
Other GHRH analogues (CJC-1295, tesamorelin): redundant — same receptor.
HGH: redundant.

For sensitive systems

Sermorelin sits in similar tolerability territory to ipamorelin and CJC-1295 no-DAC for sensitive-systems users — possibly the best-tolerated of the three for cautious starts because of the short half-life and the preserved somatostatin feedback loop. The pulse comes and goes quickly; the body’s natural counter-regulation responds normally; the per-dose physiological footprint is small.

Start dose for sensitive users. 100 mcg subQ at bedtime, paired with 100 mcg ipamorelin if stacking. Hold for 1–2 weeks before considering an increase.

Ramp. If tolerated, increase to 200 mcg sermorelin / 200 mcg ipamorelin after 1–2 weeks. Most sensitive users find 200 mcg sufficient. The move from 200 to 300 mcg is a smaller felt-effect step than 100 to 200.

Expected adjustment profile:

Injection-site reactions — pain, redness, mild swelling at the injection site — were the most common AE in the original paediatric trials (~16% of patients) and remain the most consistently reported issue with sermorelin specifically.
Mild headache in the first few days — vasoactive, GH/IGF-1-driven fluid shifts.
Transient flushing at injection — usually local.
Tingling, numbness, or carpal-tunnel-like sensations — fluid retention pressing on peripheral nerves. Less common with sermorelin than with CJC-1295 DAC because the per-dose elevation is smaller and shorter.
Vivid dreaming in the first 1–2 weeks — common across the GH-secretagogue category.

Sermorelin’s short half-life means that adjustment-profile symptoms typically resolve within hours rather than persisting through the day. This makes ramping easier — you can identify a tolerance issue quickly.

What’s not normal and warrants stopping: sustained headache, persistent paraesthesia that doesn’t reverse on dose reduction, blood pressure elevation, joint pain that wasn’t there at baseline, atypical chest sensations.

For MCAS / histamine-sensitive users. No specific histamine activity documented. The receptor target (GHRH-R) is not directly mast-cell-relevant. Injection-site reactions are local and not generally indicative of systemic mast-cell activation.

For POTS users. The smallest fluid-retention footprint of any compound in the GH cluster. Monitor for orthostatic worsening in the first 2 weeks; if absent, sermorelin is generally well-tolerated in this population.

For UARS / chronic fatigue / ME/CFS. Sleep-architecture effects are the most defensible benefit. Sermorelin + ipamorelin is the cleanest “physiological” pairing in this population because both compounds preserve natural pulse patterns. Worth a 4-week trial.

For active or recent cancer history. Same relative contraindication as ipamorelin and CJC-1295. GH/IGF-1 axis stimulation is theoretically mitogenic for some tumour types; the mechanism is the same as exogenous HGH (contraindicated in active or recent cancer). Treat as a relative contraindication for active malignancy, recent (within ~5 years) malignancy of GH/IGF-1-responsive types (breast, prostate, colon, certain endocrine tumours), MEN syndromes, or strong family history without screening in place.

Interactions worth considering:

HGH: redundant.
Other GHRH analogues: redundant.
Other GHRPs (GHRP-2, GHRP-6, hexarelin): add to the pulse but remove the selectivity advantage of pairing with ipamorelin specifically.
Insulin / metformin / GLP-1 agonists: GH transiently raises blood glucose. Usually subclinical in well-controlled users.
Steroids: exogenous corticosteroids blunt GHRH pulse response.
SSRIs, SNRIs, LDN, beta-blockers: no documented interactions.

Reasonable expectations

Onset. Subjective sleep changes (deeper sleep, vivid dreams, easier wake-ups) are typically reported within the first 1–2 weeks. Body composition changes, where they occur, take 6–12 weeks.

Response rate. Sleep-quality response is the most consistently reported subjective effect across the GH-secretagogue category — rough community signal of ~70% reporting clear sleep changes with sermorelin + ipamorelin. Body-composition response is more variable.

What the evidence actually supports.

GH pulse on demand, paediatric efficacy — supported by published trials underlying the original FDA approval.
Preserved somatostatin feedback — mechanistically clean.
Short-term tolerability — supported by the paediatric trial record.

What the evidence does not support.

Adult body composition outcomes at any specific magnitude — no controlled trial measured this.
Anti-ageing or longevity claims — speculative for sermorelin specifically.
“Restored youthful GH levels” — common marketing language; not the outcome the trials were designed to measure.

What not to expect.

HGH-equivalent effects. Sermorelin produces GH pulses; HGH delivers sustained elevation. Effects of HGH at therapeutic doses are larger and faster.
Effect without fasted dosing. A fed dose blunts the GH pulse substantially.
Effect without ipamorelin (or another GHRP). Sermorelin alone produces a smaller pulse than the stack. The synergy is the reason for the pairing.

Cost

US (compounded prescription path — the standard route)

Compounded sermorelin is widely available through 503A pharmacies in the US under physician prescription. Approximate monthly costs (2026):

Component	Typical monthly cost
Compounded sermorelin (medication only)	$150–$350
Combined sermorelin + ipamorelin (formulated together)	$200–$500
Provider supervision / consultation	$50–$100
Injection supplies	$20–$50
Total monthly (medication + supervision + supplies)	$220–$650

Pricing varies by pharmacy, dose, and prescriber. The compounded path is more expensive per mg than research-chemical sermorelin but includes the prescriber relationship, pharmacy quality oversight, and clear legal posture.

UK (no licensed pathway)

Sermorelin is not available through any UK licensed pharmacy — there is no MHRA-approved sermorelin product. UK users access sermorelin through the same research-chemical channels as ipamorelin and CJC-1295.

Research-chemical UK market (vendor-neutral estimate):

5 mg vials: ~£25–60
Combined sermorelin + ipamorelin blend vials (5 mg + 5 mg): ~£40–90
Monthly cost at 200 mcg/day, 5 days/week, stacked with ipamorelin: ~£40–100/month

Sensitive-start economics

A user starting at 100 mcg/day uses half the compound, so a 5 mg vial covers ~50 doses — roughly 2.5 months at 5-on/2-off cycling. This is the most cost-efficient starting position regardless of access route.

Reconstitution

This section covers reconstitution of research-chemical sermorelin for users in markets without compounded access (UK, EU, most non-US jurisdictions). US users with compounded prescription sermorelin generally receive pre-reconstituted vials with pharmacy-printed concentration labels, or detailed mixing instructions specific to that pharmacy’s batch — follow those rather than the generic guidance below.

What’s in the box

Research-chemical sermorelin ships as lyophilised white powder in a glass vial, typically 5 mg or 10 mg per vial. Compounded sermorelin from US pharmacies is more commonly supplied at 3 mg, 9 mg, or 15 mg depending on the pharmacy’s standard formulation; if you have compounded product, follow the pharmacy’s specific reconstitution guidance.

You’ll also need:

Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol. Required for the standard ~28-day stability window.
Insulin syringe (U-100) — 1 mL with 29G–31G needle. 100 units = 1 mL.
A larger syringe (3 mL or 5 mL) for transferring BAC water into the vial.
Alcohol wipes, a clean working surface, somewhere to record what you did.

The math

The standard sermorelin reconstitution mirrors the ipamorelin / CJC-1295 no-DAC convention:

5 mg vial, 2 mL BAC water (the standard)

Concentration: 2.5 mg/mL (2,500 mcg/mL)
100 mcg = 0.04 mL = 4 units (right at the readability floor)
200 mcg = 0.08 mL = 8 units
300 mcg = 0.12 mL = 12 units
500 mcg = 0.2 mL = 20 units

5 mg vial, 2.5 mL BAC water (for sensitive-start / low-dose users)

Concentration: 2 mg/mL (2,000 mcg/mL)
100 mcg = 0.05 mL = 5 units
200 mcg = 0.1 mL = 10 units

Stacked with ipamorelin. Same logic as CJC-1295 + ipamorelin: either reconstitute separately at 2.5 mg/mL each and draw both into the same syringe, or use a vendor-supplied combined blend. 200 mcg sermorelin + 200 mcg ipamorelin from separate 2.5 mg/mL vials = 8 units + 8 units = 16 units total in one bedtime injection.

The Peptrax Vial Plan calculator handles the same math interactively — enter your vial size, BAC volume, and dose, and it returns draw volume and doses per vial.

Reconstitution procedure

Wipe the rubber stopper of the lyophilised vial and the BAC water vial with alcohol.
Draw the chosen volume of BAC water into the larger syringe.
Insert the needle into the lyophilised vial at an angle, with the tip touching the inside wall above the powder. Inject the water slowly down the inside of the vial, not directly onto the powder. Forcing water onto lyophilised peptide can denature it.
Leave the vial undisturbed for 1–2 minutes. Do not shake. Gently swirl if needed; the powder dissolves on its own.
Once the solution is clear, label the vial: compound, concentration, reconstitution date.
Store refrigerated (2–8°C / 36–46°F).

Some practitioners pass the reconstituted solution through a 0.22 µm syringe filter as a belt-and-braces sterility step. Optional rather than standard.

Storage and stability

Sermorelin reconstituted with BAC water has stability data in the same range as the rest of the GH-secretagogue cluster:

Conservative: 14–21 days refrigerated
Middle: 28 days refrigerated (the most commonly cited figure across community sources)
Optimistic: 30–90 days (some 503A compounding pharmacies assign longer beyond-use dates based on USP guidelines and formulation-specific stability data; this depends on conditions that don’t apply to typical research-chem reconstitutions)

The honest middle is 28 days at 2–8°C. Store at the back of the refrigerator. Do not freeze.

If you reconstitute with plain sterile water instead of BAC water, the vial is single-use — discard within 24 hours.

For a 5 mg vial dosed at 200 mcg/day, 5 days/week: 25 doses → 5 weeks of theoretical doses, just over the 4-week stability window. Most users finish within shelf life. Sensitive-start users at 100 mcg/day get 50 doses → 10 weeks of theoretical doses but only 4 weeks of stability; plan for some product loss.

Areas of concern ⚠

The evidence gap (especially for adult biohacker use)

Sermorelin’s documented efficacy is in paediatric growth hormone deficiency — children with documented low GH whose linear growth was the trial endpoint. Adult use, anti-ageing use, and biohacker recovery use rest on:

The mechanism (GHRH-R agonism produces a GH pulse — well-supported)
A smaller adult-onset GHD evidence base (supportive but smaller-N and shorter-duration than the paediatric record)
Extrapolation from GH biology generally (the chain GH pulse → IGF-1 → favourable body composition is plausible but each step is inferred)

For a sceptical reader: sermorelin produces a GH pulse, that’s documented. Whether that GH pulse changes anything you care about over a 12-week protocol in an otherwise-healthy adult is genuinely an open question.

Long-term safety in healthy adults is uncharacterised

The longest durations in the registrational paediatric trials are months, not years. Multi-year safety in healthy biohacker-population adults is unknown. Mechanistic concerns are the same as for the rest of the GH cluster:

IGF-1 elevation — broadly anabolic, theoretically mitogenic for GH/IGF-1-responsive tumour types
Insulin sensitivity — GH transiently antagonises insulin
Pituitary feedback — chronic GHRH-R stimulation may downregulate receptors over months; community cycling pattern is precautionary

Cancer / tumour-growth concern

Same framing as the rest of the GH cluster. GH/IGF-1 elevation is plausibly mitogenic; sermorelin specifically has not been studied in cancer populations. Treat as a relative contraindication for:

Active malignancy of any type
Recent (within ~5 years) malignancy of GH/IGF-1-responsive types — breast, prostate, colon, certain endocrine tumours
Multiple Endocrine Neoplasia syndromes
Strong family history of GH/IGF-1-responsive cancers without screening in place

Quality and sourcing — a meaningful split between US and UK

For US users with prescribed compounded sermorelin from a registered 503A pharmacy: sourcing is the closest to “regulated medicine” of any compound in this encyclopedia, though “compounded” still means “not FDA-approved as a final product” — the pharmacy compounds against an FDA bulks-list ingredient under state Board of Pharmacy oversight.

For UK users (and US users on the research-chemical path): standard research-chem caveats apply. No batch testing at point of sale, variable purity, no MHRA / FDA oversight of the final product. This is materially riskier than the US compounded path and is the same risk level as research-chem ipamorelin or CJC-1295.

Populations where sermorelin is contraindicated or high-risk

Active or recent cancer history (relative contraindication; see above)
Active acromegaly or known pituitary adenoma
Pregnancy and breastfeeding — no safety data
Type 1 diabetes — GH antagonises insulin
Severe insulin resistance / poorly-controlled type 2 diabetes — same concern, smaller margin
Sleep apnoea (untreated) — GH/IGF-1 effects on soft tissue may worsen airway collapse
Severe hypothyroidism (untreated) — GH response is blunted; treat thyroid first

Measurement and dosing pitfalls

mg vs mcg confusion. 1 mg = 1,000 mcg. A “300” dose is 300 mcg, not 300 mg.
Reading “units” as mg. Units are a volume mark on the syringe.
Ignoring the fasted-dosing requirement. A fed dose produces substantially less GH pulse.
Mistaking compounded sermorelin’s pharmacy-supplied concentration for the research-chem standard. Compounded vials are labelled with their actual concentration, which may differ from the 2.5 mg/mL research-chem default. Read the pharmacy label.
Buying “sermorelin” that’s actually CJC-1295 no-DAC. Some research-chem vendors substitute or mislabel; the molecules are similar enough to look the same on a label but pharmacologically different (twice the half-life, different per-injection profile). Lab-tested vendors are the meaningful quality signal.

What the community gets wrong

“Sermorelin and CJC-1295 are interchangeable.” Pharmacologically similar, not identical. The half-life difference (~12 vs ~30 minutes) means per-injection pulse magnitude differs, and the FDA-history credibility of sermorelin is unique to it.
“FDA-approved means safe for everything sermorelin is sold for.” It was approved for paediatric GHD with linear growth as the endpoint. Adult anti-ageing, recovery, body composition use is off-label extrapolation that may or may not produce the outcomes the marketing claims.
“Compounded means FDA-approved.” Compounded medications are not FDA-reviewed for safety or effectiveness as final products. The 503A pathway uses FDA-approved bulk substances but the compounded preparation itself is not an FDA-approved drug.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Previously approved as Geref (1997–2009); NDA withdrawn for commercial reasons explicitly not for safety or effectiveness (Federal Register, May 2009). Currently accessible through 503A compounding pharmacies under physician prescription. The 2024 FDA Category 2 actions targeting ipamorelin, CJC-1295, AOD-9604, and thymosin alpha-1 did not include sermorelin, leaving its compounding-pharmacy status more secure than other GH-cluster peptides.	2026-04-29
UK (MHRA)	Not approved. No licensed sermorelin product. Sold as a research chemical under “research use only / not for human consumption” labelling, which permits sale of the raw peptide but does not authorise human use.	2026-04-29
EU (EMA)	Not approved. No licensed product.	2026-04-29
WADA (sport)	Prohibited. Listed under S2 (Peptide Hormones, Growth Factors, and Related Substances). In and out of competition.	2026-04-29

Narrative. Sermorelin’s regulatory story is the most stable of any GH-axis peptide in this encyclopedia. The historical FDA approval, the 2009 Federal Register notice confirming non-safety-related withdrawal, and the unchallenged 503A compounding-pharmacy access in the US together create the cleanest legal and provenance pathway in the GH-secretagogue category. For UK readers, that pathway does not extend across the Atlantic — research-chemical purchase remains the only access route, with the same legal grey area as ipamorelin or CJC-1295.

For athletes and any user considering competitive sport: sermorelin is on the WADA prohibited list. The short half-life means the parent compound clears quickly, but the GH pulse signature it produces may be detectable for longer.

What to track in Peptrax

Two users on “sermorelin 200 mcg daily” can be running fundamentally different protocols depending on access route. The US user with a 503A compounded prescription has a pharmacy, a prescribed concentration, and a beyond-use date that the protocol comes with. The UK user on the research-chem path has a vendor, a batch, a reconstitution date, and a self-chosen BAC volume. Logging the access route up front determines which metadata fields actually matter.

For most users, the highest-signal log is subjective sleep quality and morning state across the first 4–8 weeks — the same pattern as the rest of the GH cluster. Sermorelin’s short half-life means felt effects, where present, are bound to the bedtime injection itself rather than persisting through the day; daily sleep-quality ratings (1–5) and morning subjective recovery alongside the dose log give the cleanest read on whether the compound is doing anything for the user specifically.

For sensitive-systems users, the priority log is the first 2–3 weeks: injection-site reactions (sermorelin’s most-reported AE), any fluid-retention symptoms, blood-pressure changes, and anything that carries forward through the day rather than resolving with the half-life. Sermorelin’s pulse arrives and clears quickly, so a symptom that persists is worth flagging — it usually indicates a dose-response issue rather than a sermorelin-specific problem.

Across all users, logging stack composition matters: sermorelin alone, sermorelin + ipamorelin, dose ratio, time of injection relative to last meal. The synergy with ipamorelin is the reason most users see results, and reconstructing what worked later requires the full setup not just the dose. Vial reconstitution date matters because the 28-day stability window genuinely constrains the protocol — and, for users on compounded prescriptions, the pharmacy beyond-use date overrides it.

For personal tracking and informational purposes only — not medical advice.